ArticleeLife2019
A toolbox of nanobodies developed and validated for use as intrabodies and nanoscale immunolabels in mammalian brain neurons.
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders.Molecular psychiatry · 2026Review
- Article
- 3D STED Super-Resolution Imaging Strategy for Visualizing Synaptic Nano-architecture in Brain Cryosections.Bio-protocol · 2026Article
- Article
- A versatile cohesion manipulation system probes female reproductive age-related egg aneuploidy.Nature aging · 2025Article
- Open-source antibodies as a path to enhanced research reproducibility and transparency.New biotechnology · 2025Article
- Combining nanobody labeling with STED microscopy reveals input-specific and layer-specific organization of neocortical synapses.PLoS biology · 2025Article
- Genetically encoded intrabody probes for labeling and manipulating AMPA-type glutamate receptors.Nature communications · 2024Article
- High-throughput development and characterization of new functional nanobodies for gene regulation and epigenetic control in human cells.bioRxiv : the preprint server for biology · 2024Article
- Diagnostic and Therapeutic Aptamers: A Promising Pathway to Improved Cardiovascular Disease Management.JACC. Basic to translational science · 2024Review
- Article
- Single-cell synaptome mapping: its technical basis and applications in critical period plasticity research.Frontiers in neural circuits · 2024Review
- Engineering memory with an extrinsically disordered kinase.Science advances · 2023Article
- Peptide-PAINT Using a Transfected-Docker Enables Live- and Fixed-Cell Super-Resolution Imaging.Small methods · 2023Article
- Quantitative DNA-PAINT imaging of AMPA receptors in live neurons.Cell reports methods · 2023Article
- Regulating voltage-gated ion channels with nanobodies.Nature communications · 2022Article
- Engineered fast-dissociating antibody fragments for multiplexed super-resolution microscopy.Cell reports methods · 2022Article
- Review
- Development and Validation of Arc Nanobodies: New Tools for Probing Arc Dynamics and Function.Neurochemical research · 2022Article
- A Versatile Synthetic Affinity Probe Reveals Inhibitory Synapse Ultrastructure and Brain Connectivity.Angewandte Chemie (International ed. in English) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Nanobodies (nAbs) are small, minimal antibodies that have distinct attributes that make them uniquely suited for certain biomedical research, diagnostic and therapeutic applications. Prominent uses include as intracellular antibodies or intrabodies to bind and deliver cargo to specific proteins and/or subcellular sites within cells, and as nanoscale immunolabels for enhanced tissue penetration and improved spatial imaging resolution. Here, we report the generation and validation of nAbs against a set of proteins prominently expressed at specific subcellular sites in mammalian brain neurons. We describe a novel hierarchical validation pipeline to systematically evaluate nAbs isolated by phage display for effective and specific use as intrabodies and immunolabels in mammalian cells including brain neurons. These nAbs form part of a robust toolbox for targeting proteins with distinct and highly spatially-restricted subcellular localization in mammalian brain neurons, allowing for visualization and/or modulation of structure and function at those sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.